Search Results - "GOLDMAN, JOHN"

Disease Selection: The Way Disease Changed the World by Goldman, John

Get full text

How I treat chronic myeloid leukemia in the imatinib era by Goldman, John M.

“…Although it is now generally accepted that imatinib is the best initial treatment for patients newly diagnosed with chronic myeloid leukemia (CML) in chronic…”
Get full text

Chronic myeloid leukemia: mechanisms of blastic transformation by Perrotti, Danilo, Jamieson, Catriona, Goldman, John, Skorski, Tomasz

“…The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid leukemia (CML). Patients with early phase (also known as chronic phase [CP])…”
Get full text

Chronic Myeloid Leukemia: A Historical Perspective by Goldman, John M

“…Patients with splenomegaly and abnormally high leukocyte counts were first recognized in France, Germany, and Scotland in the 1840s. The only well-documented…”
Get full text

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors by MARIN, David, IBRAHIM, Amr R, PAVLU, Jiri, PALIOMPEIS, Christos, REID, Alistair, REZVANI, Katayoun, GOLDMAN, John M, FORONI, Letizia, LUCAS, Claire, GERRARD, Gareth, LIHUI WANG, SZYDLO, Richard M, CLARK, Richard E, APPERLEY, Jane F, MILOJKOVIC, Dragana, BUA, Marco

“…We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to…”
Get full text

Ponatinib for Chronic Myeloid Leukemia by Goldman, John M

“…The treatment of patients with chronic myeloid leukemia (CML) must be ranked as one of the great medical success stories of the past 30 years. The…”
Get full text

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 by Baccarani, Michele, Deininger, Michael W., Rosti, Gianantonio, Hochhaus, Andreas, Soverini, Simona, Apperley, Jane F., Cervantes, Francisco, Clark, Richard E., Cortes, Jorge E., Guilhot, François, Hjorth-Hansen, Henrik, Hughes, Timothy P., Kantarjian, Hagop M., Kim, Dong-Wook, Larson, Richard A., Lipton, Jeffrey H., Mahon, François-Xavier, Martinelli, Giovanni, Mayer, Jiri, Müller, Martin C., Niederwieser, Dietger, Pane, Fabrizio, Radich, Jerald P., Rousselot, Philippe, Saglio, Giuseppe, Saußele, Susanne, Schiffer, Charles, Silver, Richard, Simonsson, Bengt, Steegmann, Juan-Luis, Goldman, John M., Hehlmann, Rüdiger

“…Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A…”
Get full text

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis by DE LAVALLADE, Hugues, APPERLEY, Jane F, MARIN, David, KHORASHAD, Jamshid S, MILOJKOVIC, Dragana, REID, Alistair G, BUA, Marco, SZYDLO, Richard, OLAVARRIA, Eduardo, KAEDA, Jaspal, GOLDMAN, John M

“…Imatinib is remarkably effective in treating newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase (CP). To date, most of the available…”
Get full text

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) by Hughes, Timothy P., Hochhaus, Andreas, Branford, Susan, Müller, Martin C., Kaeda, Jaspal S., Foroni, Letizia, Druker, Brian J., Guilhot, François, Larson, Richard A., O'Brien, Stephen G., Rudoltz, Marc S., Mone, Manisha, Wehrle, Elisabeth, Modur, Vijay, Goldman, John M., Radich, Jerald P.

“…This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the…”
Get full text

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib by Marin, David, Hedgley, Corinne, Clark, Richard E., Apperley, Jane, Foroni, Letizia, Milojkovic, Dragana, Pocock, Christopher, Goldman, John M., O'Brien, Stephen

“…Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia, but not all patients respond well. We analyzed the outcome of…”
Get full text

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet by Baccarani, Michele, Cortes, Jorge, Pane, Fabrizio, Niederwieser, Dietger, Saglio, Giuseppe, Apperley, Jane, Cervantes, Francisco, Deininger, Michael, Gratwohl, Alois, Guilhot, François, Hochhaus, Andreas, Horowitz, Mary, Hughes, Timothy, Kantarjian, Hagop, Larson, Richard, Radich, Jerald, Simonsson, Bengt, Silver, Richard T, Goldman, John, Hehlmann, Rudiger

“…To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine…”
Get full text

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib by MARIN, David, BAZEOS, Alexandra, PALIOMPEIS, Christos, LATHAM, Victoria, FORONI, Letizia, MOLIMARD, Mathieu, REID, Alistair, REZVANI, Katy, DE LAVALLADE, Hugues, GUALLAR, Cristina, GOLDMAN, John, KHORASHAD, Jamshid S, MAHON, Francois-Xavier, ELIASSON, Lina, MILOJKOVIC, Dragana, BUA, Marco, APPERLEY, Jane F, SZYDLO, Richard, DESAI, Ritti, KOZLOWSKI, Kasia

“…There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These…”
Get full text

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials by Branford, Susan, Fletcher, Linda, Cross, Nicholas C.P., Müller, Martin C., Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald P., Saglio, Giuseppe, Pane, Fabrizio, Kamel-Reid, Suzanne, Wang, Y. Lynn, Press, Richard D., Lynch, Kevin, Rudzki, Zbigniew, Goldman, John M., Hughes, Timothy

“…An international basis for comparison of BCR-ABL mRNA levels is required for the common interpretation of data derived from individual laboratories. This will…”
Get full text

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias by Walker, Christopher J., Oaks, Joshua J., Santhanam, Ramasamy, Neviani, Paolo, Harb, Jason G., Ferenchak, Gregory, Ellis, Justin J., Landesman, Yosef, Eisfeld, Ann-Kathrin, Gabrail, Nash Y., Smith, Carrie L., Caligiuri, Michael A., Hokland, Peter, Roy, Denis Claude, Reid, Alistair, Milojkovic, Dragana, Goldman, John M., Apperley, Jane, Garzon, Ramiro, Marcucci, Guido, Shacham, Sharon, Kauffman, Michael G., Perrotti, Danilo

“…As tyrosine kinase inhibitors (TKIs) fail to induce long-term response in blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia…”
Get full text

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure by Cortes, Jorge, Goldman, John M, Hughes, Timothy

“…Despite the success with tyrosine kinase inhibitors (TKIs) in most patients with chronic myelogenous leukemia (CML), some patients still experience resistance…”
Get more information

Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state by Gadhiya, Kinjal P, Hansrivijit, Panupong, Gangireddy, Mounika, Goldman, John D

“…ObjectiveCOVID-19 is a respiratory disease caused by SARS-CoV-2 with the highest burden in the USA. Data on clinical characteristics of patients with COVID-19…”
Get full text

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results by Hughes, Timothy, Deininger, Michael, Hochhaus, Andreas, Branford, Susan, Radich, Jerald, Kaeda, Jaspal, Baccarani, Michele, Cortes, Jorge, Cross, Nicholas C.P., Druker, Brian J., Gabert, Jean, Grimwade, David, Hehlmann, Rüdiger, Kamel-Reid, Suzanne, Lipton, Jeffrey H., Longtine, Janina, Martinelli, Giovanni, Saglio, Giuseppe, Soverini, Simona, Stock, Wendy, Goldman, John M.

“…The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chronic myeloid leukemia (CML) and the second generation of…”
Get full text

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor by Marin, David, Milojkovic, Dragana, Olavarria, Eduardo, Khorashad, Jamshid S., de Lavallade, Hugues, Reid, Alistair G., Foroni, Letizia, Rezvani, Katayoun, Bua, Marco, Dazzi, Francesco, Pavlu, Jiri, Klammer, Matthias, Kaeda, Jaspal S., Goldman, John M., Apperley, Jane F.

“…The majority of patients with chronic myeloid leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or lose their initial…”
Get full text

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy by Ibrahim, Amr R., Eliasson, Lina, Apperley, Jane F., Milojkovic, Dragana, Bua, Marco, Szydlo, Richard, Mahon, Francois-Xavier, Kozlowski, Kasia, Paliompeis, Christos, Foroni, Letizia, Khorashad, Jamshid S., Bazeos, Alex, Molimard, Mathieu, Reid, Alistair, Rezvani, Katayoun, Gerrard, Gareth, Goldman, John, Marin, David

“…We studied the relation between adherence to imatinib measured with microelectronic monitoring systems and the probabilities of losing a complete cytogenetic…”
Get full text

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies by Oaks, Joshua J., Santhanam, Ramasamy, Walker, Christopher J., Roof, Steve, Harb, Jason G., Ferenchak, Greg, Eisfeld, Ann-Kathrin, Van Brocklyn, James R., Briesewitz, Roger, Saddoughi, Sahar A., Nagata, Kyosuke, Bittman, Robert, Caligiuri, Michael A., Abdel-Wahab, Omar, Levine, Ross, Arlinghaus, Ralph B., Quintas-Cardama, Alfonso, Goldman, John M., Apperley, Jane, Reid, Alistair, Milojkovic, Dragana, Ziolo, Mark T., Marcucci, Guido, Ogretmen, Besim, Neviani, Paolo, Perrotti, Danilo

“…FTY720 (Fingolimod, Gilenya) is a sphingosine analog used as an immunosuppressant in multiple sclerosis patients. FTY720 is also a potent protein phosphatase…”
Get full text